WO2001020031A3 - Polymorphismes dans un gene klotho - Google Patents

Polymorphismes dans un gene klotho Download PDF

Info

Publication number
WO2001020031A3
WO2001020031A3 PCT/GB2000/003457 GB0003457W WO0120031A3 WO 2001020031 A3 WO2001020031 A3 WO 2001020031A3 GB 0003457 W GB0003457 W GB 0003457W WO 0120031 A3 WO0120031 A3 WO 0120031A3
Authority
WO
WIPO (PCT)
Prior art keywords
polymorphisms
klotho gene
methods
disease
predisposition
Prior art date
Application number
PCT/GB2000/003457
Other languages
English (en)
Other versions
WO2001020031A2 (fr
Inventor
Kazuhide Hasegawa
Yasuhiro Kikuchi
Hirofumi Nakano
Helen Molloy
Mathias Chiano
Original Assignee
Kyowa Hakko Kogyo Kk
Kazuhide Hasegawa
Yasuhiro Kikuchi
Hirofumi Nakano
Helen Molloy
Mathias Chiano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9921485.0A external-priority patent/GB9921485D0/en
Application filed by Kyowa Hakko Kogyo Kk, Kazuhide Hasegawa, Yasuhiro Kikuchi, Hirofumi Nakano, Helen Molloy, Mathias Chiano filed Critical Kyowa Hakko Kogyo Kk
Priority to EP00958842A priority Critical patent/EP1210426A2/fr
Priority to AU70257/00A priority patent/AU7025700A/en
Priority to JP2001523802A priority patent/JP2003514513A/ja
Publication of WO2001020031A2 publication Critical patent/WO2001020031A2/fr
Publication of WO2001020031A3 publication Critical patent/WO2001020031A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)

Abstract

L'invention concerne des procédés et des moyens permettant de diagnostiquer une maladie ou une prédisposition à une maladie par génotypage d'un gène klotho à partir d'un individu et identification de l'existence d'au moins un risque de polymorphisme. Ces risques sont associés, directement ou indirectement, à la prédisposition à une gamme de maladies chroniques, notamment l'ostéoporose, des troubles cutanés, des maladies liées à l'âge, des dysfonctionnements pulmonaires et des syndromes métaboliques. L'invention traite en outre de procédés de traitement, de trousses de diagnostic et d'un gène klotho isolé comprenant tout ou partie d'une gamme de polymorphismes, ainsi que de procédés d'isolation de molécules modulant un gène klotho.
PCT/GB2000/003457 1999-09-10 2000-09-08 Polymorphismes dans un gene klotho WO2001020031A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00958842A EP1210426A2 (fr) 1999-09-10 2000-09-08 Polymorphismes dans un gene klotho
AU70257/00A AU7025700A (en) 1999-09-10 2000-09-08 Polymorphisms in a klotho gene
JP2001523802A JP2003514513A (ja) 1999-09-10 2000-09-08 クロソ遺伝子中の多型

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9921485.0A GB9921485D0 (en) 1999-09-10 1999-09-10 Polymorphisms in a klotho gene
GB9921485.0 1999-09-10
GB0006171.3 2000-03-14
GB0006171A GB0006171D0 (en) 1999-09-10 2000-03-14 Polymorphisms in a klotho gene

Publications (2)

Publication Number Publication Date
WO2001020031A2 WO2001020031A2 (fr) 2001-03-22
WO2001020031A3 true WO2001020031A3 (fr) 2002-03-14

Family

ID=26243878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003457 WO2001020031A2 (fr) 1999-09-10 2000-09-08 Polymorphismes dans un gene klotho

Country Status (4)

Country Link
EP (1) EP1210426A2 (fr)
JP (1) JP2003514513A (fr)
AU (1) AU7025700A (fr)
WO (1) WO2001020031A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0112075D0 (en) * 2001-05-17 2001-07-11 Univ Aberdeen Diagnostic method for osteoporosis and related disorders
JP4696294B2 (ja) * 2004-08-30 2011-06-08 学校法人慶應義塾 評価方法、ヒト・エストロゲン受容体遺伝子、ゲノムｄｎａ、及び診断マーカー
PE20090227A1 (es) 2007-04-02 2009-04-03 Genentech Inc Composiciones farmaceuticas que comprenden agentes anti-beta-klotho
EP2152295B1 (fr) 2007-05-08 2018-04-18 Tel HaShomer Medical Research Infrastructure and Services Ltd. Protéine klotho et composés apparentés destinés au traitement du cancer
US10555963B2 (en) 2007-05-08 2020-02-11 Tel Hashomer Medical Research Infrastructure And Services Ltd. Klotho protein and related compounds for the treatment and diagnosis of cancer
WO2010064247A1 (fr) 2008-12-03 2010-06-10 Tel Hashomer Medical Research Infrastructure And Services Ltd. Procédés et trousses pour déterminer une prédisposition au cancer
EP2431463A4 (fr) 2009-05-13 2012-12-26 Shionogi & Co Agent d'essai pour l'obésité viscérale et son utilisation
CN102465182A (zh) * 2010-10-29 2012-05-23 株式会社爱茉莉太平洋 检测皮肤活性物质的检测试剂盒和检测皮肤活性物质的方法
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
CN106957921B (zh) * 2017-05-18 2020-12-29 中国水产科学研究院珠江水产研究所 一种适合食人工配合饲料大口黑鲈klotho基因的SNP位点及其在育种中的应用
EA035077B1 (ru) * 2017-08-14 2020-04-24 Федеральное Государственное Бюджетное Научное Учреждение "Научно Исследовательский Институт Медицины Труда Имени Академика Н.Ф. Измерова" (Фгбну "Нии Мт") Способ прогнозирования риска развития синтропии бронхиальной астмы и метаболического синдрома
EP3879271A1 (fr) * 2020-03-10 2021-09-15 SALION GmbH Détection de klotho
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BONE (OSAKA) (1999), 13(3), 89-95 *
CHEMICAL ABSTRACTS, vol. 128, no. 18, 4 May 1998, Columbus, Ohio, US; abstract no. 216023, NAGAI, RYOZO ET AL: "Molecular genetics of cardiovascular diseases" XP002172678 *
CHEMICAL ABSTRACTS, vol. 132, no. 12, 20 March 2000, Columbus, Ohio, US; abstract no. 149834, KAWAGUCHI, HIROSHI: "klotho gene and bone metabolism" XP002172677 *
MATSUMURA, Y. ET AL.: "Identification of the Human Klotho Gene and Its Two Transcripts Encoding Membrane and Secreted Klotho Protein", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 242, 1998, pages 626 - 630, XP002172676 *
OGATA, N. ET AL.: "Association of Polymorphism of Human Klotho Locus with Lumbar Spondilosys", J. BONE AND MINERAL RES., vol. 14, no. Suppl.1, 1999, pages S340, XP001010330 *
RINSHO BYORI (1998), 46(3), 249-257 *
YAMASHITA, T. ET AL.: "Elongation of the epiphyseal trabecular bone in transgenic mice carrying a klotho gene locus mutation that leads to a syndrome resembling aging", J. ENDOCRINOL., vol. 159, 1998, pages 1 - 8, XP002172675 *

Also Published As

Publication number Publication date
EP1210426A2 (fr) 2002-06-05
AU7025700A (en) 2001-04-17
WO2001020031A2 (fr) 2001-03-22
JP2003514513A (ja) 2003-04-22

Similar Documents

Publication Publication Date Title
WO2001020031A3 (fr) Polymorphismes dans un gene klotho
WO2006002262A3 (fr) Genes et voies exprimes de maniere differentielle dans des troubles bipolaires et/ou troubles depressifs majeurs
WO2005055808A3 (fr) Compositions et methodes pour le diagnostic et le traitement du cancer du poumon
WO2006044860A3 (fr) Composes de thiadiazole et leurs procedes d'utilisation
WO2008070672A3 (fr) Compositions et procédés pour le traitement du cancer avec des cuprédoxines et de l'adn riche en cpg
WO2006122046A3 (fr) Therapies pour maladies vasculaires
WO2007063405A3 (fr) Diagnostic et traitement des dysfonctionnements de l'exocrine pancreas et des diabetes
WO2007002088A3 (fr) Psat1s servant de modificateurs de la voie pten/akt et procedes pour les utiliser
WO2006009962A3 (fr) Acacs utilises comme genes modificateurs de la voie igf et leurs procedes d'utilisation
WO2004047727A3 (fr) Compositions et procedes pour diagnostiquer et traiter des troubles de l'humeur
WO2001020026A3 (fr) Polymorphismes du gene humain hpxr et leur utilisation dans des applications diagnostiques et therapeutiques
WO2005016287A3 (fr) Prkwnk utilises en tant que modificateurs de la voie rac et methodes d'utilisation associees
AU2904197A (en) Diagnostic method and apparatus based on polymorphism in an IL-6 gene
WO2006009924A3 (fr) Pfk utilises comme modificateurs de la voie igfr et leurs methodes d'utilisation
WO2001077380A3 (fr) Sequences
WO2005002418A3 (fr) Mpten en tant que modulateurs du passage pten/igf et procedes d'utilisation
WO2006036613A3 (fr) Genes mrac utilises en tant que modificateurs de la voie rac et procedes d'utilisation correspondants
WO2005003297A3 (fr) Genes mpten utilises en tant que modificateurs de la voie pten/igf et procedes d'utilisation associes
WO2000012754A8 (fr) Procede d'identification de substances pour le traitement de troubles induits par la c-jun
WO2006099185A3 (fr) Brsk1s modulateurs de la voie de signalisation pten/akt et procede d'utilisation
CA2388933A1 (fr) Utilisation de parvovirus pour ameliorer l'etat general de patients souffrant de tumeurs ou de patients souffrant de maladies chroniques ou du type cachexique
WO2004048538A3 (fr) Caseine kinases modifiant la voie rac et leurs procedes d'utilisation
WO2005017118A3 (fr) Sulf utilises comme modificateurs de la voie beta-catenine et procedes associes
WO2005017123A3 (fr) Mptens utilises comme modificateurs de la voie pten et procedes d'utilisation
WO2005003305A3 (fr) Usp utilises en tant que modificateurs de la voie beta-catenine et procedes associes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 523802

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000958842

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000958842

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000958842

Country of ref document: EP